Latest news

Serodus' Article of Association 25 April 2019

Serodus ASA has successfully completed a directed share issue of NOK 499.200.

Serodus’ Board of Directors has, based on the issue authorization granted by the annual general meeting on 29 May 2018, issued new shares at a subscription price of NOK 1.30. The Company received NOK 499.200.

The proceeds of the Share Issue will be used for: 1) finalization of the ongoing regulatory required toxicological testing before long-term administration of SER150 in clinical trials, 2) production of clinical material and 3) preparation of the coming clinical trial in diabetic patients with kidney disease.

1Q 2019 reporting

DOWNLOAD REPORT

The highlights from 1Q 2019:

  • Preparing for the next financing round
  • Initiated SER150 long-term toxicological testing in 2 animal species
  • Submitted a novel SER150 patent application

Serodus' Articles of Association March 2019

Articles of Association March 16 2019

Serodus ASA (the “Company”) has successfully completed a directed share issue of NOK 27,4 million.

Serodus’ Board of Directors has, based on the issue authorization granted by the annual general meeting on 29 May 2018, issued new shares at a subscription price of NOK 1.30. The Company received NOK 27,4 million.

The proceeds of the Share Issue will be used for: 1) finalization of the ongoing regulatory required toxicological testing before long-term administration of SER150 in clinical trials, 2) production of clinical material and 3) preparation of the coming clinical trial in diabetic patients with kidney disease.